US 12,497,401 B2Granted

Substituted tetrazoles as TRPA1 inhibitors

AssigneeBoehringer Ingelheim International GmbH

InventorsMartin Thomas Fleck, Florian Paul Christian Binder, Georg Dahmann, Joerg P. Hehn, Uta Friederike Lessel, Jens Willwacher

Life of this patent

Estimating the term…

Abstract

This invention related to substituted tetrazoles and their use as inhibitors of TRPA1 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of fibrotic diseases, inflammatory and auto-immune diseases and CNS-related diseases.

Claims7

Dependent claims

A compound selected from the group consisting of

or a salt thereof.

Dependencies are inferred from the claim text.

Facts

Application: 17/767,486Filed 14 Oct 2020
Priority: EP 1920317415 Oct 2019
Published: US 2024/0101561 A128 Mar 2024
Granted: 16 Dec 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61P 13/00
Drugs for disorders of the urinary system
C07D 487/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61K 31/522
Purines, e.g. adenine: having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/53
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having six-membered rings with three nitrogens as the only ring hetero…

Family

US 2024/0101561 A1Pre-grant publication · published 28 Mar 2024
US 12,497,401 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results